Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Collegium to Acquire U.S. Rights to Nucynta Franchise
2 Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020
3 Collegium Pharmaceutical Inc (COLL) Q3 2020 Earnings Call Transcript
4 Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
5 Nucynta ER poses lower risk for abuse than other opioids
6 Collegium Announces Closing of the Nucynta Franchise Acquisition
7 Asia-Pacific Roundup: TGA cancels three breast implants
8 Tapentadol Market Analysis Share Size, Demand, Key Players and Explorer Growth Trends by Forecast 2025
9 Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference
10 Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference
11 Lower Rates of Abuse With Nucynta ER vs Other ER Opioids
12 Assertio Therapeutics still depends on sales of opioid Nucynta
13 Nucynta ER Approved For Moderate To Severe Chronic Pain Control
14 FDA Approves Nucynta for Pain Associated with Diabetic Peripheral Neuropathy
15 Janssen Pharmaceuticals, Inc. Completes Divestiture of US License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.
16 Assertio Therapeutics Announces Favorable Nucynta® Patent Ruling
17 Depomed Prevails in NUCYNTA Franchise ANDA Litigation Providing Market Exclusivity Until December 2025
18 FDA Targets Websites Selling Illicit Opioids
19 Grünenthal changes partner for US opioid drug marketing
20 Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
21 Tapentadol Market Key Players and Competitive Landscape Report
22 Actavis Confirms Generic Nucynta® ER Patent Challenge
23 BRIEF-Assertio Therapeutics Announces Sale Of Nucynta Franchise To Collegium Pharmaceutical For $375.0 Million
24 Collegium Pharma (COLL) Announces FY19 Product Revenue Guidance for Xtampza ER and Nucynta
25 J&J Close to Reaching $4 Billion Agreement to Settle Thousands of Opioid Lawsuits, Sources Say
26 New York files civil insurance fraud charges against Johnson & Johnson in opioid case
27 Collegium Reports First Quarter 2020 Profitability Nasdaq:COLL
28 Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise
29 A Deep Look At Depomed's Billion-Dollar Bet On Nucynta
30 Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
31 New York Files Insurance Fraud Lawsuit Against J&J
32 J&J Offers $4 Billion Opioid Litigation Settlement
33 FDA approves wider use for J&J Nucynta ER pain drug
34 Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
35 Collegium Pharmaceutical Inc (COLL) Q1 2020 Earnings Call Transcript
36 Collegium Pharmaceutical Inc (COLL) Q2 2020 Earnings Call Transcript
37 The Call On Collegium Pharmaceuticals
38 Collegium Reports Full-Year 2019 Revenue of $296.7 Million
39 Depomed pays over $1 billion for US rights to Janssen's Nucynta franch
40 Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020
41 Depomed wins Nucynta patent fight, but does that harm or help in proxy battle?
42 Collegium Pharmaceutical Just Updated Its 2020 Guidance. Is It a Buy?
43 New Jersey sues pharmaceutical company over opioid crisis
44 Depomed Distances Itself From Nucynta
45 New Jersey Sues Janssen Pharmaceuticals Over Two Opioid Drugs
46 AG Ferguson sues opioid manufacturer Johnson & Johnson over state's opioid epidemic
47 Should You Buy This Biotech That Makes A Lower Risk Painkiller?
48 NUCYNTA™ (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain
49 Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting
50 New option for acute pain treatment
51 Assertio Therapeutics Announces First-Quarter 2020 Results Nasdaq:ASRT
52 Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance
53 Editorial: Why Are ER Opioids Out of Favor?
54 After Purdue Opioid Settlement, Oklahoma Sets Sights on New Target in Lawsuit
55 Texas Accuses Johnson & Johnson of Opioid-Related Fraud
56 Shaking Down Drug Makers Won't Stop IV Drug Users
57 Kentucky accuses J&J of contributing to opioid epidemic
58 Assertio Reports Third Quarter 2020 Financial Results
59 Johnson & Johnson to pay $20.4 million as part of Ohio opioid lawsuits settlement
60 Ohio counties, drug companies outline arguments in landmark opioid trial
61 Depomed Executes an Exit Strategy for Its Opioid Drug
62 Tapentadol is 'Third-Tier' Drug for Diabetic Neuropathic Pain
63 Grünenthal GmbH v. Alkem Labs. Ltd. | Robins Kaplan LLP
64 Opinion: Legal payouts by J&J and Purdue are only a start. Consumers must change their drug habits
65 What Is Your Tapering Story?
66 Scrutiny Of Painkiller Distributors Harms Patients
67 STATELINE-Opioid Crisis ‘Kingpin’ Is Oklahoma’s New Target in Lawsuit
68 'SELL BABY SELL!': Unsealed documents in opioids lawsuit reveal inner workings of industry's marketing machine
69 Collegium Reports Third Quarter 2019 Financial Results Nasdaq:COLL
70 Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
71 Johnson & Johnson adds $1B to opioid lawsuits settlement pool, bringing total to $5B
72 Tapentadol-ER for the Treatment of Diabetes Associated Peripheral Neuropathy (DPN)
73 Lakeport sues opioid manufacturers, distributors for opioid epidemic
74 As J&J seeks to dismiss opioid lawsuit in NJ, it reaches settlement with Ohio counties
75 J&J's greed helped fuel U.S. opioid crisis, Oklahoma claims at trial
76 J&J Fights Opioid 'Kingpin' Label by Noting 1% Market Share
77 Exclusive: Drugmaker Depomed prepares to explore a sale
78 Drug Makers Focusing on Pain Management Alternatives to Opioid Drugs
79 Needham Issues a Buy Rating on Collegium Pharmaceutical (COLL)
80 Probe: Firefighters tried to hide overdose | News, Sports, Jobs
81 Polymorphic Patent Survives Obviousness Challenge | McDermott Will & Emery
82 FDA Requires Boxed Warnings for Deadly Opioid-Benzo Combo Risks
83 Why Collegium Pharmaceutical Stock Is Crushing It Today
84 Serotonin syndrome: Causes, symptoms, and treatment
85 CTI BioPharma Accelerated Review, And Other News: The Good, Bad, And Ugly Of Biopharma
86 How Johnson & Johnson companies used a 'super poppy' to make narcotics for America's most abused opioid pills
87 NJ opioid lawsuit vs. Johnson & Johnson subsidiary OK, 'public nuisance' claim shot down
88 Alex Reish received thousands from pharmaceutical companies while serving on Colorado DUR board
89 Opioid 'kingpin' J&J fueled epidemic, Oklahoma argues at trial's end
90 Depomed CEO has fended off multiple takeovers with strategic thinking
91 After opioids, learning to feel pain normally again
92 Tapentadol Toxicity in Children
93 Is an opioid really the best medication for my pain?
94 Will J&J be Able to Overcome Its Legal Troubles in 2020?
95 Practitioner as Patient: Understanding the Disparities of Chronic Pain in CRPS
96 Neuropathic Pain Market to Garner a Valuation of US$ 9862.3 Million by 2027, at CAGR of 6.4%, Globa
97 Horizon Pharma Withdraws Hostile Offer for Depomed
98 Assertio Therapeutics Announces Strong Second-Quarter 2019 Results
99 UBER, NLOK among premarket gainers
100 Collegium loses bid to escape Purdue's opioid patent lawsuit